– This transition is expected to eliminate approximately 24,000 tCO2e of greenhouse gas emissions annually, helping the company achieve its carbon emissions targets. – The switch to biomass briquettes strengthens Piramal Pharma Limited’s sustainability practices and sets a new industry standard for environmentally friendly production.
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635) has achieved a remarkable environmental milestone at its API and intermediates manufacturing facility in Digwal, India, by converting its coal-fired steam boiler to run on biomass briquettes, a renewable energy source has. This is an important step towards Piramal’s sustainability goal of reducing greenhouse gas emissions (Scope 1 and 2) by 42% by 2030. The strategic conversion of the Digwal facility will eliminate approximately 24,000 tonnes of carbon dioxide equivalent (tCO2e) of greenhouse gas emissions annually, representing approximately 17% of the company’s total emissions.
“The switch to biomass briquettes at our Digwal facility is a testament to our commitment to reducing our environmental footprint while driving innovation in sustainable production. By aligning our goals with global climate action frameworks, we will continue to contribute to a more sustainable future for generations to come,” said Nandini Piramal, Chairman, Piramal Pharma Limited.
The introduction of biomass briquettes is an important step towards sustainability at Piramal. These briquettes are pressed blocks of biomass that are processed and compacted under high pressure. Biomass briquettes, made from agricultural waste, are a renewable fuel source that supports circular economy principles by recycling organic by-products, reducing waste and promoting sustainability.
“This transformation at our Digwal facility underscores our commitment to environmental stewardship and sustainable operations,” said Peter DeYoung, Managing Director of Piramal Global Pharma. “By switching to biomass briquettes, we are significantly reducing our greenhouse gas emissions and setting new industry standards for responsible pharmaceutical manufacturing.”
This initiative supports Piramal’s global sustainability goals and demonstrates how pharmaceutical companies can implement effective climate solutions while maintaining operational excellence. Piramal Pharma Limited remains committed to responsible growth through eco-friendly practices to support a greener future.
Information about Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE:PPLPHARMA I BSE:543635) offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing company, as well as Piramal Critical Care (PCC), a complex generics business for hospitals, and the India Consumer Healthcare business, a company that sells consumer and wellness products. Additionally, one of PPL’s affiliates, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has established itself as one of the ophthalmology leaders in the Indian pharmaceutical market.
Further information can be found at: Piramal Pharma | LinkedIn
*Includes an attachment relating to PPL’s minority interest in Yapan Bio.
Photo: https://mma.prnewswire.com/media/2598532/Nandini_Piramal.jpg
Photo: https://mma.prnewswire.com/media/2598529/Peter_DeYoung_CEO_Piramal.jpg
Photo: https://mma.prnewswire.com/media/2598531/Biomass_Briquettes_Piramal.jpg
Photo: https://mma.prnewswire.com/media/2598530/16_TPH_Solid_Fuel_Boiler_Piramal.jpg
Logo: https://mma.prnewswire.com/media/2538752/5117211/Piramal_Pharma_Limited_Logo.jpg